LXEO - Lexeo Therapeutics, Inc.

2.36
0.540   22.881%

Share volume: 2,978,524
Last Updated: 04-09-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.03%

PREVIOUS CLOSE
CHG
CHG%
$1.82
0.54
0.30%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 0%
Dept financing 4%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
31.84%
1 Month
-9.92%
3 Months
-63.07%
6 Months
-70.35%
1 Year
-81.10%
2 Year
-76.52%
Key data
Stock price
$2.36
P/E Ratio 
0.00
DAY RANGE
$1.75 - $2.64
EPS 
-$3.09
52 WEEK RANGE
$1.45 - $19.50
52 WEEK CHANGE
-$81.93
MARKET CAP 
217.574 M
YIELD 
N/A
SHARES OUTSTANDING 
33.061 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
2.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,664,807
AVERAGE 30 VOLUME 
$1,238,588
Company detail
CEO: R. Nolan Townsend
Region: US
Website: www.lexeotx.com
Employees: 0
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

We are a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Our principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York.

Recent news
loading